Blincyto (blinatumomab) - Important Safety Information from AMGEN Ireland Limited as approved by the HPRA

Notice type: 3rd Party Publications

Date: 25/10/2016

 

Problem Or Issue:
Important Safety Information communication from AMGEN Ireland Limited on risk of pancreatitis associated with Blincyto (blinatumomab).

Important Safety Information - Blincyto (blinatumomab)
 


« Back